Published in Neurology on September 12, 2012
Neuroinflammation and Cognitive Decline in Alzheimer Disease (NICAD) | NCT02377206
White matter hyperintensities and their penumbra lie along a continuum of injury in the aging brain. Stroke (2014) 1.68
Pathology and pathogenesis of vascular cognitive impairment-a critical update. Front Aging Neurosci (2013) 1.27
The overlap between vascular disease and Alzheimer's disease--lessons from pathology. BMC Med (2014) 1.15
Are empirically-derived subtypes of mild cognitive impairment consistent with conventional subtypes? J Int Neuropsychol Soc (2013) 1.14
Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain (2015) 1.09
Reconsidering harbingers of dementia: progression of parietal lobe white matter hyperintensities predicts Alzheimer's disease incidence. Neurobiol Aging (2014) 1.08
Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimers Dement (2015) 0.98
Aggregate effects of vascular risk factors on cerebrovascular changes in autopsy-confirmed Alzheimer's disease. Alzheimers Dement (2014) 0.92
Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology. Curr Alzheimer Res (2016) 0.90
Clinical and imaging features of mixed Alzheimer and vascular pathologies. Alzheimers Res Ther (2015) 0.87
Cross-sectional and longitudinal relationships between cerebrospinal fluid biomarkers and cognitive function in people without cognitive impairment from across the adult life span. JAMA Neurol (2014) 0.86
A kernel machine method for detecting effects of interaction between multidimensional variable sets: an imaging genetics application. Neuroimage (2015) 0.86
The effect of white matter hyperintensities on neurodegeneration in mild cognitive impairment. Alzheimers Dement (2015) 0.85
Association of white matter hyperintensities and gray matter volume with cognition in older individuals without cognitive impairment. Brain Struct Funct (2015) 0.83
METACOHORTS for the study of vascular disease and its contribution to cognitive decline and neurodegeneration: An initiative of the Joint Programme for Neurodegenerative Disease Research. Alzheimers Dement (2016) 0.83
Understanding cognitive deficits in Alzheimer's disease based on neuroimaging findings. Trends Cogn Sci (2013) 0.83
β-amyloid deposition is shifted to the vasculature and memory impairment is exacerbated when hyperhomocysteinemia is induced in APP/PS1 transgenic mice. Alzheimers Res Ther (2014) 0.82
Mixed pathology is more likely in black than white decedents with Alzheimer dementia. Neurology (2015) 0.81
Stroke risk interacts with Alzheimer's disease biomarkers on brain aging outcomes. Neurobiol Aging (2015) 0.81
Cerebral white matter hyperintensities in the prediction of cognitive decline and incident dementia. Int Rev Psychiatry (2013) 0.81
Weaker circadian activity rhythms are associated with poorer executive function in older women. Sleep (2014) 0.80
Longitudinal change of small-vessel disease-related brain abnormalities. J Cereb Blood Flow Metab (2016) 0.80
Vascular disease and risk factors are associated with cognitive decline in the alzheimer disease spectrum. Alzheimer Dis Assoc Disord (2015) 0.79
Intravital imaging in spontaneously hypertensive stroke-prone rats-a pilot study. Exp Transl Stroke Med (2014) 0.79
Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2. Alzheimers Dement (2015) 0.79
The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015. Alzheimers Dement (2015) 0.78
Insight of brain degenerative protein modifications in the pathology of neurodegeneration and dementia by proteomic profiling. Mol Brain (2016) 0.78
Longitudinal effects of metabolic syndrome on Alzheimer and vascular related brain pathology. Dement Geriatr Cogn Dis Extra (2014) 0.78
The role of cerebrovascular disease when there is concomitant Alzheimer disease. Biochim Biophys Acta (2015) 0.77
Peripheral (deep) but not periventricular MRI white matter hyperintensities are increased in clinical vascular dementia compared to Alzheimer's disease. Brain Behav (2016) 0.77
Contribution of cerebrovascular health to the diagnosis of Alzheimer disease. JAMA Neurol (2013) 0.76
Cerebral Amyloid and Hypertension are Independently Associated with White Matter Lesions in Elderly. Front Aging Neurosci (2015) 0.76
Amyloid Dysmetabolism Relates to Reduced Glucose Uptake in White Matter Hyperintensities. Front Neurol (2016) 0.75
Hippocampal atrophy but not white-matter changes predicts the long-term cognitive response to cholinesterase inhibitors in Alzheimer's disease. Alzheimers Res Ther (2015) 0.75
Ex vivo MRI transverse relaxation in community based older persons with and without Alzheimer's dementia. Behav Brain Res (2016) 0.75
Independent value added by diffusion MRI for prediction of cognitive function in older adults. Neuroimage Clin (2017) 0.75
White matter hyperintensities are more highly associated with preclinical Alzheimer's disease than imaging and cognitive markers of neurodegeneration. Alzheimers Dement (Amst) (2016) 0.75
Vascular Health and Genetic Risk Affect Mild Cognitive Impairment Status and 4-Year Stability: Evidence From the Victoria Longitudinal Study. J Gerontol B Psychol Sci Soc Sci (2015) 0.75
Tract-specific white matter hyperintensities disrupt neural network function in Alzheimer's disease. Alzheimers Dement (2016) 0.75
The Effect of Vascular Neuropathology on Late-life Cognition: Results from the SMART Project. J Prev Alzheimers Dis (2016) 0.75
Framingham Coronary Heart Disease Risk Score Can be Predicted from Structural Brain Images in Elderly Subjects. Front Aging Neurosci (2014) 0.75
A Systematic Review of Longitudinal Studies Which Measure Alzheimer's Disease Biomarkers. J Alzheimers Dis (2017) 0.75
Vascular burden and brain aging in a senior volunteer cohort: A pilot study. Ci Ji Yi Xue Za Zhi (2017) 0.75
Models for longitudinal data: a generalized estimating equation approach. Biometrics (1988) 27.90
General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation (2008) 26.42
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging (2008) 14.68
Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA (1997) 10.75
Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology (2007) 9.27
Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology (2009) 7.04
Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 5.55
Cerebral white matter lesions and cognitive function: the Rotterdam Scan Study. Ann Neurol (2000) 5.34
Stroke risk profile predicts white matter hyperintensity volume: the Framingham Study. Stroke (2004) 4.56
Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med (2009) 4.45
Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA (2007) 4.03
Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging (2009) 3.97
The effect of white matter hyperintensity volume on brain structure, cognitive performance, and cerebral metabolism of glucose in 51 healthy adults. Neurology (1995) 3.95
Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci (2005) 3.84
Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. Neurology (2004) 3.61
Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun Study. Neurology (2002) 2.87
Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol (2009) 2.85
Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging (2000) 2.77
Cognitive impact of subcortical vascular and Alzheimer's disease pathology. Ann Neurol (2006) 2.62
Longitudinal change of biomarkers in cognitive decline. Arch Neurol (2011) 2.51
Longitudinal study of blood pressure and white matter hyperintensities: the EVA MRI Cohort. Neurology (2001) 2.18
Vascular factors predict rate of progression in Alzheimer disease. Neurology (2007) 2.06
Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. Arch Neurol (2010) 1.94
Cerebral structure on MRI, Part I: Localization of age-related changes. Biol Psychiatry (1991) 1.73
Microinfarcts, brain atrophy, and cognitive function: the Honolulu Asia Aging Study Autopsy Study. Ann Neurol (2011) 1.65
Cardiovascular risk factors and incident Alzheimer disease: a systematic review of the literature. Alzheimer Dis Assoc Disord (2009) 1.64
PENN biomarker core of the Alzheimer's disease Neuroimaging Initiative. Neurosignals (2007) 1.54
Cerebrovascular disease, β-amyloid, and cognition in aging. Neurobiol Aging (2011) 1.37
Resting-state brain glucose utilization as measured by PET is directly related to regional synaptophysin levels: a study in baboons. Neuroimage (2003) 1.33
Gray matter reduction is correlated with white matter hyperintensity volume: a voxel-based morphometric study in a large epidemiological sample. Neuroimage (2005) 1.25
Coronary risk correlates with cerebral amyloid deposition. Neurobiol Aging (2011) 1.17
Cognitive and anatomic contributions of metabolic decline in Alzheimer disease and cerebrovascular disease. Arch Neurol (2008) 0.98
Early oligodendrocyte/myelin pathology in Alzheimer's disease mice constitutes a novel therapeutic target. Am J Pathol (2010) 0.96
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol (2013) 9.43
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain (2009) 7.20
Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain (2008) 6.29
Comparing predictors of conversion and decline in mild cognitive impairment. Neurology (2010) 5.69
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol (2010) 5.53
Multimodal classification of Alzheimer's disease and mild cognitive impairment. Neuroimage (2011) 5.24
Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol (2015) 5.10
Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Arch Neurol (2003) 4.82
MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain (2009) 4.51
Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain (2010) 4.39
Automatic classification of patients with Alzheimer's disease from structural MRI: a comparison of ten methods using the ADNI database. Neuroimage (2010) 4.28
Relationships between biomarkers in aging and dementia. Neurology (2009) 4.16
Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol (2008) 4.15
Spatial patterns of brain atrophy in MCI patients, identified via high-dimensional pattern classification, predict subsequent cognitive decline. Neuroimage (2007) 4.07
Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging (2009) 3.97
The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement (2010) 3.85
Anatomical mapping of white matter hyperintensities (WMH): exploring the relationships between periventricular WMH, deep WMH, and total WMH burden. Stroke (2004) 3.80
Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet (2012) 3.73
MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology (2009) 3.72
Prevalence of dementia in older latinos: the influence of type 2 diabetes mellitus, stroke and genetic factors. J Am Geriatr Soc (2003) 3.60
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology (2012) 3.58
Multi-modal multi-task learning for joint prediction of multiple regression and classification variables in Alzheimer's disease. Neuroimage (2011) 3.47
Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects. Neuroimage (2008) 3.40
The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement (2010) 3.30
Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort. Neuroimage (2010) 3.27
Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology (2005) 3.14
Fast and robust multi-atlas segmentation of brain magnetic resonance images. Neuroimage (2009) 3.13
Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement (2010) 3.11
Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol (2012) 3.03
FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain (2007) 2.96
Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. Radiology (2009) 2.90
Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative. Alzheimers Dement (2010) 2.88
Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer's disease. PLoS One (2009) 2.85
Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol (2012) 2.84
Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol (2011) 2.83
MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology (2009) 2.83
Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Neuroimage (2009) 2.80
Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans. Alzheimers Dement (2010) 2.79
Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 2. Arch Neurol (2003) 2.70
Voxelwise genome-wide association study (vGWAS). Neuroimage (2010) 2.69
Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement (2010) 2.68
Cognitive impact of subcortical vascular and Alzheimer's disease pathology. Ann Neurol (2006) 2.62
Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. AJNR Am J Neuroradiol (2010) 2.61
Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer's disease. Brain (2009) 2.61
Early diagnosis of Alzheimer's disease using cortical thickness: impact of cognitive reserve. Brain (2009) 2.51
Longitudinal change of biomarkers in cognitive decline. Arch Neurol (2011) 2.51
Bias in tensor based morphometry Stat-ROI measures may result in unrealistic power estimates. Neuroimage (2011) 2.50
Spatially augmented LPboosting for AD classification with evaluations on the ADNI dataset. Neuroimage (2009) 2.47
Automatic quality assessment in structural brain magnetic resonance imaging. Magn Reson Med (2009) 2.43
Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol (2011) 2.41
3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry. Neuroimage (2008) 2.40
Subregional neuroanatomical change as a biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 2.37
Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer's disease. Neuroimage (2010) 2.32
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2013) 2.32
Multi-modal imaging predicts memory performance in normal aging and cognitive decline. Neurobiol Aging (2008) 2.31
Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer's disease mild cognitive impairment, and elderly controls. Neuroimage (2008) 2.30
Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database. Brain (2008) 2.28
Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: an ADNI study of 515 subjects. Neuroimage (2009) 2.28
Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Hum Brain Mapp (2009) 2.28
Discovering genetic associations with high-dimensional neuroimaging phenotypes: A sparse reduced-rank regression approach. Neuroimage (2010) 2.27
Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Neuroimage (2008) 2.25
Structural MRI biomarkers for preclinical and mild Alzheimer's disease. Hum Brain Mapp (2009) 2.24
Bias in estimation of hippocampal atrophy using deformation-based morphometry arises from asymmetric global normalization: an illustration in ADNI 3 T MRI data. Neuroimage (2009) 2.22
Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology (2010) 2.20
Association of lifetime cognitive engagement and low β-amyloid deposition. Arch Neurol (2012) 2.20
Regional rates of neocortical atrophy from normal aging to early Alzheimer disease. Neurology (2009) 2.18
CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease. J Neurosci (2010) 2.18
Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol (2010) 2.16
Boosting power for clinical trials using classifiers based on multiple biomarkers. Neurobiol Aging (2010) 2.13
A commonly carried allele of the obesity-related FTO gene is associated with reduced brain volume in the healthy elderly. Proc Natl Acad Sci U S A (2010) 2.12
Statistical analysis of longitudinal neuroimage data with Linear Mixed Effects models. Neuroimage (2012) 2.11
LEAP: learning embeddings for atlas propagation. Neuroimage (2009) 2.09
The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes. Alzheimers Dement (2010) 2.09
MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults. Neurology (2011) 2.08
White matter changes compromise prefrontal cortex function in healthy elderly individuals. J Cogn Neurosci (2006) 2.06
Alzheimer's disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition. Neuroimage (2009) 2.03
Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology (2014) 2.03
Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not β-amyloid in cognitively normal older individuals. J Neurosci (2013) 2.01
Homocysteine, B vitamins, and the incidence of dementia and cognitive impairment: results from the Sacramento Area Latino Study on Aging. Am J Clin Nutr (2007) 1.98
Multidimensional classification of hippocampal shape features discriminates Alzheimer's disease and mild cognitive impairment from normal aging. Neuroimage (2009) 1.95
Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative. Arch Gen Psychiatry (2011) 1.94
Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. Arch Neurol (2010) 1.94
Genome-wide analysis reveals novel genes influencing temporal lobe structure with relevance to neurodegeneration in Alzheimer's disease. Neuroimage (2010) 1.94
Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease. Brain (2013) 1.91
Genome-wide association study of Alzheimer's disease. Transl Psychiatry (2012) 1.88
Relationships between β-amyloid and functional connectivity in different components of the default mode network in aging. Cereb Cortex (2011) 1.87
Estimating the age of healthy subjects from T1-weighted MRI scans using kernel methods: exploring the influence of various parameters. Neuroimage (2010) 1.87
Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects. Neurology (2010) 1.86
Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden. Brain (2010) 1.86